Gadobutrol

• Long-term impact of GBCAs on motor and cognitive function following repeated Contrast-Enhanced MRI—ODYSSEY Pending
  2024-515462-14-00 Phase IV 3 countries Iqvia Rds France
• Phase IV, single-center, randomized, crossover clinical trial to validate the use of gadopiclenol versus gadobutrol in the evaluation of mag… Pending
  2025-523278-18-00 Phase IV 1 country Fundacio Hospital Universitari Vall D’Hebron Institut De Recerca
• Multimodal Imaging with FAPI-PET/MRI in Breast Carcinoma-In-Situ for Detection of occult Invasive cancer (MI-CISDIR) Recruiting
  2023-509860-47-00 Phase II 1 country Universitaet Muenster
• Temporal characterization of Extracellular Vesicles during cellular therapy using CAR-T cells and during the occurrence of Immune effector C… Recruiting
  2024-515328-35-00 Phase IV 1 country Centre Hospitalier Universitaire De Saint Etienne
• Evaluating safety, efficacy and pharmacokinetics of a modified regimen of ublituximab (ENHANCE) Recruiting
  2024-519284-18-00 Phase III 1 country Tg Therapeutics Inc.
• Intrathecal MRI Contrast for Assessment of CSF Transport Recruiting
  2024-519936-18-00 Phase IV 1 country Oslo University Hospital HF
• MRI contrast agent in the spinal canal to investigate transportation of the cerebrospinal fluid in the brain. Recruiting
  2024-520146-33-00 Phase I/II 1 country Region Vaesterbotten
• A clinical trial to be conducted in many hospitals and in different countries with the medicinal substance Regadenoson to be used in a type … Recruiting
  2024-515244-22-00 Phase I/II 3 countries GE Healthcare Limited
• Hyperpolarized 129-Xenon MRI in Fibrosing Interstitial Lung Disease Ended
  2022-502512-36-00 Phase II 1 country Aarhus University
• A study to evaluate the safety and effectiveness of a new gene therapy (XC001) for people with coronary artery disease and reduced heart fun… Ended
  2025-521325-33-00 Phase II 4 countries Xylocor Therapeutics Inc.
• A study to test how well BI 3720931 is tolerated and whether it improves lung function in people with cystic fibrosis (LenticlairTM 1) Ended
  2023-503281-23-00 Phase I (FiH) 4 countries Boehringer Ingelheim Espana S.A.; Boehringer Ingelheim International GmbH
• A study to test whether BI 765845 helps people who have had a heart attack Ended
  2022-502788-39-00 Phase II 7 countries Boehringer Ingelheim Espana S.A.; Boehringer Ingelheim International GmbH; Boehr…
• A study to compare how well gadoquatrane works and its safety with an already available contrast agent for MRI in people with known or suspe… Ended
  2022-501884-41-00 Phase III 7 countries Bayer AG
• A study to compare the effects and safety of gadoquatrane with an already used available contrast agent for MRI tests in people with any kno… Ended
  2022-501885-24-00 Phase III 8 countries Bayer AG
• A Phase 2 double-blind, randomized, placebo-controlled study evaluating the effect of SAR443820 on serum neurofilament levels in participant… Ended
  2023-509078-45-00 Phase II 7 countries Sanofi-Aventis Recherche & Developpement
• Glenzocimab in Anterior stroke with Large Ischemic Core eligible for Endovascular therapy Ended
  2023-509615-92-00 Phase II 1 country Hopital Fondation Adolphe De Rothschild

Showing 1–16 of 16 trials